The Use of Fetal Fibronectin to Predict Delivery Due to Abruptio Placenta
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01279369
Recruitment Status :
(Quantitative assessment of fFN only able to be performed at one laboratory.)
The purpose of this study is to determine if the presence of fetal fibronectin in the cervicovaginal secretions of pregnant patients with minor maternal trauma predicts impending preterm delivery due to abruptio placenta.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients eligible for inclusion in the study are women aged 18 or over with singleton intrauterine pregnancy ≥20 weeks gestational age and ≤35 weeks gestational age presenting to the Winthrop University Hospital Labor & Delivery triage unit with a chief complaint of maternal trauma.
Singleton intrauterine pregnancy ≥20 weeks and ≤35 weeks gestational age
Chief complaint of minor maternal trauma including motor vehicle accident, patient fall or assault with absence of maternal conditions outlined in exclusion criteria
Unstable vital signs
Head injury resulting in coma
signs or symptoms of intraperitoneal bleeding
Emergency laparotomy for fetal or maternal indications
History of previous abruptio placenta
Known or suspected placenta previa
Rupture of membranes
Advanced cervical dilatation ≥3cm
Non-reassuring fetal status requiring intervention
Vaginal bleeding on presentation
History of intercourse and/or digital vaginal exam and/or vaginal ultrasound ≤24 hours prior to presentation